What do systematic reviews say?

Serlopitant 0.25 mg vs placebo

Serlopitant 0.25 mg showed no clear difference in patient‐reported pruritus intensity compared with placebo (low certainty).

• Interventions for chronic pruritus of unknown origin 2020 · Cochrane Headline outcomes only
  RR 1.66 [1, 2.77]
  1 study · 127 participants
  Low

Serlopitant 0.25 mg vs placebo

It is very uncertain whether serlopitant 0.25 mg changes adverse events compared with placebo (very low certainty).

• Interventions for chronic pruritus of unknown origin 2020 · Cochrane Headline outcomes only
  RR 1.29 [0.75, 2.24]
  1 study · 127 participants
  Very low

Serlopitant 0.25 mg vs placebo

• Interventions for chronic pruritus of unknown origin 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 127 participants
  Very low

Serlopitant 0.25 mg vs placebo

It is very uncertain whether serlopitant 0.25 mg changes sleep disturbances: number of participants with insomnia compared with placebo (very low certainty).

• Interventions for chronic pruritus of unknown origin 2020 · Cochrane Headline outcomes only
  RR 0.6 [0.31, 1.17]
  1 study · 127 participants
  Very low

Serlopitant 0.25 mg vs placebo

The review found no eligible studies for this question.

• Interventions for chronic pruritus of unknown origin 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Serlopitant 0.25 mg vs placebo

The review found no eligible studies for this question.

• Interventions for chronic pruritus of unknown origin 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found